Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ryoichi Nagata
AddedMar 31, 2024
UpdatedMay 1, 2026
Ryoichi Nagata

Ryoichi Nagata

Board Member, Snbl USA

Ryoichi Nagata's Career

Snbl USA
Snbl USA

Everett, WA, US

Board Member· Board
Shin Nippon Biomedical Laboratories
Shin Nippon Biomedical Laboratories

Tokyo, Tokyo, JP

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ryoichi Nagata's Career

Snbl USA
Snbl USA
7501999Everett, WA, US
Board Member· Board

Leadership at Snbl USA

Ken TakanashiKen TakanashiBoard Member

Similar to Snbl USA

BLC USABLC USANashville, TN, USDrug Developmentest. 2017BLC USANashville, TN, US · est. 2017

BLC USA: A Nashville-based medical R&D firm combating global drug-resistant bacteria crisis.

Seed · $813.3k6
Nascent BiotechNascent BiotechSan Diego, CA, USCancer Treatmentest. 2009Nascent BiotechSan Diego, CA, US · est. 2009

Nascent Biotech, Inc.: A biotech firm specializing in developing and delivering cancer-treating antibodies.

Public · $3.9M2
Rjs BiologicsRjs BiologicsSeattle, WA, USMedicines, Pharmaceuticalsest. 2009Rjs BiologicsSeattle, WA, US · est. 2009

RJS Biologics: Innovating critical treatments as a leading pharmaceutical manufacturer.

Angel · $225k5
BlinkBioBlinkBioJupiter, FL, USCancer Therapiesest. 2009BlinkBioJupiter, FL, US · est. 2009

BlinkBio, a biotech firm, leverages its TDC platform to design innovative cancer therapies using BLink chemistries, founded in 2009 in Florida.

Seed · $20.7M7
Shin Nippon Biomedical Laboratories
Shin Nippon Biomedical Laboratories
Public7501957Tokyo, Tokyo, JP
Board Member· Board

Similar to Shin Nippon Biomedical Laboratories

Snbl USASnbl USAEverett, WA, USDevelopment, Researchest. 1999Snbl USAEverett, WA, US · est. 1999

Everett-based SNBL U.S.A., Ltd. offers comprehensive biological and physical R&D services across the U.S.

750
Shionogi & Co.Shionogi & Co.Osaka, Osaka Prefecture, JPDiagnostics, Pharmaceuticalsest. 1878Shionogi & Co.Osaka, Osaka Prefecture, JP · est. 1878

Shionogi & Co., Ltd.: A Japanese pharmaceutical firm specializing in prescription drugs and diagnostics.

Public · $7.6M5.3k
ONO PharmaceuticalONO PharmaceuticalCambridge, MA, USDiagnostics, Pharmaceuticalsest. 1717ONO PharmaceuticalCambridge, MA, US · est. 1717

ONO Pharmaceutical: A US-based global leader in innovative pharmaceuticals and diagnostic reagents since 1717.

Public3k
NovartisNovartisBasel, Basel-Stadt, CHPharmaceuticalsest. 2002NovartisBasel, Basel-Stadt, CH · est. 2002

Innovative Swiss-American pharma creating transformative treatments.

Public · $6.5M101.7k

Ryoichi Nagata's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Ryoichi Nagata

Kojiro KinoshitaKojiro KinoshitaBoard Member · Nissan Chemicalnobuyuki nakagawanobuyuki nakagawaBoard Member · MynaviHiroshi YanoHiroshi YanoBoard Member · Nagoya Railroad Co.Norio TadakawaNorio TadakawaBoard Member · Shiseido Company